Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12349337 | 0.81 | RXFP1 (0.54) | MAPTTP53LMNATHRBHTR1A | |
| SCHEMBL12349344 | 0.75 | POLB (0.44) | MAPTTP53LMNATHRBHTR1A | |
| SCHEMBL12349341 | 0.74 | RXFP1 (0.56) | MAPTTP53LMNATHRBHTR1A | |
| SCHEMBL12349301 | 0.73 | MAPT (0.40) | MAPTTP53LMNATHRBHTR1A | |
| SCHEMBL12349307 | 0.73 | MAPT (0.40) | MAPTTP53LMNATHRBHTR1A | |
| SCHEMBL12349338 | 0.72 | RXFP1 (0.54) | MAPTTP53LMNATHRBHTR1A | |
| SCHEMBL12349334 | 0.71 | RXFP1 (0.53) | MAPTTP53LMNATHRBHTR1A | |
| SCHEMBL12349342 | 0.71 | RXFP1 (0.41) | MAPTTP53LMNATHRBHTR1A | |
| SCHEMBL14281166 | 0.69 | RXFP1 (0.61) | MAPTTP53LMNATHRBHTR1A | |
| SCHEMBL8880847 | 0.65 | MAPT (0.49) | MAPTTP53LMNATHRBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989091-B2 | Silanes containing phenothiazine-S-oxide or phenothiazine-S,S-dioxide groups and the use thereof in OLEDs | BASF SE (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20100187980-A1 | SILANES CONTAINING PHENOTHIAZINE-S-OXIDE OR PHENOTHIAZINE-S,S-DIOXIDE GROUPS AND THE USE THEREOF IN OLEDS | BASF SE (DE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100187980-A1 | SILANES CONTAINING PHENOTHIAZINE-S-OXIDE OR PHENOTHIAZINE-S,S-DIOXIDE GROUPS AND THE USE THEREOF IN OLEDS | OPRD1, PPID, PLOD2 | MAPT 95/4885TP53 3059/4885LMNA 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.